DEA Hearing Record Signals Path to Schedule III Rescheduling Decision

Witness Roster Tilts Toward HHS Framework

The ALJ admitted 14 witnesses supporting the HHS recommendation to Schedule III and only 9 witnesses arguing for full descheduling or Schedule II placement. That imbalance isn't random. Administrative law judges control the hearing record through witness selection, cross-examination limits, and evidentiary rulings. This judge has consistently narrowed the scope to the question Congress delegated to HHS: does cannabis meet the three-part test for Schedule III under the Controlled Substances Act?

Witnesses arguing that cannabis has no abuse potential — a position that would support descheduling — were permitted to testify but faced tighter time limits and more aggressive cross-examination from DEA counsel. The judge also excluded two proposed expert witnesses who intended to argue that the Controlled Substances Act itself is unconstitutional as applied to state-legal cannabis programs. That's a constitutional question outside the ALJ's jurisdiction. But the exclusion signals where the boundaries are.

The procedural tilt matters because the ALJ's recommended decision, expected by late 2026 or early 2027, will carry significant weight when it reaches the DEA Administrator for final review. The Administrator isn't bound by the ALJ's findings. Yet overturning a well-supported recommendation requires a detailed rebuttal, and this record is being built to support Schedule III.

Evidentiary Rulings Favor Medical-Use Standard

The judge admitted into evidence all eight peer-reviewed studies submitted by HHS on cannabis's accepted medical use in treatment, while excluding four industry-funded surveys on patient outcomes that lacked control groups. Clear signal: the "currently accepted medical use" prong of the CSA analysis will be evaluated under FDA-style clinical standards, not patient testimonials or observational data.

The ruling also excluded testimony from two state regulators who intended to argue that widespread state legalization itself constitutes "accepted medical use." The judge's written order cited the Controlled Substances Act's text, which requires accepted medical use "in the United States" — meaning federal recognition, not state programs operating in defiance of federal law. This interpretation aligns with HHS's framework and forecloses one of the descheduling advocates' strongest rhetorical arguments.

The procedural record suggests the ALJ is treating this as a technical CSA analysis, not a referendum on the drug war or state sovereignty.

One notable admission: the judge allowed expert testimony on cannabis's potential for psychological dependence and withdrawal symptoms, even though those phenomena are less severe than for Schedule II substances like oxycodone. That evidence cuts both ways. It supports the "abuse potential" finding required to keep cannabis in any schedule, but it also distinguishes cannabis from the high-risk substances in Schedule I and II, which supports the HHS recommendation.

What the Record Doesn't Resolve: THCA and Hemp-Derived Products

The hearing record is silent on how rescheduling would affect THCA flower, delta-8 THC, and other hemp-derived intoxicating cannabinoids sold under the 2018 Farm Bill loophole. Not one witness was permitted to testify on that question. The judge struck two written submissions attempting to address it. The reason is straightforward: the DEA's rescheduling proceeding applies only to "marihuana" as defined in 21 U.S.C. § 802(16), which excludes hemp by statutory carve-out. THCA and delta-8 exist in a separate legal universe unless Congress or the courts say otherwise.

That omission will frustrate operators in the hemp-derived cannabinoid space who hoped rescheduling might clarify their status. It won't. If cannabis moves to Schedule III, state-licensed dispensaries will gain access to banking, 280E tax relief, and interstate commerce pathways. But the Farm Bill's 0.3% delta-9 THC threshold remains unchanged, and THCA's legal status remains a question of whether "total THC" or "delta-9 THC" controls under state and federal enforcement priorities. The ALJ isn't touching that fight.

For full background on the rescheduling process and timeline, see the CannIntel topic hub on the DEA rescheduling hearing.

The next major milestone is the close of post-hearing briefs, due September 30, 2026. After that, the ALJ will issue a recommended decision, likely in Q4 2026 or Q1 2027. The DEA Administrator's final rule could follow within 90 days or drag into 2028 if the Administrator requests supplemental briefing. One variable nobody can model: whether a new presidential administration in 2027 will replace the DEA Administrator mid-process and restart the clock.